George L. Bakris, MD, describes the design and results of the FIDELIO-DKD trial investigating the effect of finerenone on patients with chronic kidney disease. Neil B. Minkoff, MD: Dr Bakris, I ...
A new study unveiled on day 2 of ESC Congress 2021 showed finerenone, a nonsteroidal mineralocorticoid receptor antagonist, offers benefits to patients with mild to moderate CKD and type 2 diabetes.
Among patients with diabetic kidney disease (DKD), those with anemia may especially reap cardiovascular benefits from finerenone treatment. Finerenone treatment reduces cardiovascular and kidney risks ...
LONDON and SALT LAKE CITY, June 29, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ:RNLX) announces that the U.S. Food and Drug Administration (FDA) has granted De Novo marketing ...
BEAt-DKD (“Biomarker Enterprise to Attack Diabetic Kidney Disease”), a unique public private partnership, has announced the launch of a 5-year project with the aim to improve prevention and management ...
LONDON and NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that on June 13, 2024 Medicare issued a final Local Coverage Determination ("LCD") for the ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today late-breaking data from a pre-specified exploratory subgroup analysis of the FIDELIO-DKD Phase III study, in which the investigational drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results